Navigation Links
Scientists Spot Real 'Smoking Gun' in Prostate Cancer
Date:5/21/2010

Gene fusion may be behind disease, not androgen receptors, study suggests

FRIDAY, May 21 (HealthDay News) -- The primary cause of prostate cancer could be the fusion of two genes and the subsequent abnormal prostate cell growth that results when receptors for the hormone androgen get blocked, a new study reveals.

The implication is that standard efforts to treat the disease by targeting the androgen receptors might be missing the real "smoking gun," a University of Michigan Comprehensive Cancer Center team suggests.

"We need to begin to think about targeting prostate cancer by targeting the gene fusion, and not confining our approaches to androgen receptors," study author Dr. Arul Chinnaiyan, director of the Michigan Center for Translational Pathology, said in a news release. "If we're going to find a more durable therapy, we need to get at the gene fusion."

Chinnaiyan and his colleagues report their findings in the May 18 issue of Cancer Cell.

The authors note that typical prostate cancer treatments focus on drugs that attempt to slow production of androgen, the male hormone that regulates healthy prostate growth. However, such efforts usually become less effective over time as cancer cell resistance mounts, making recurrent cancer much less amenable to similar treatments.

But having earlier identified a so-called "on switch" for prostate cancer development in the form of the initial fusion of a prostate gene with a cancer-causing gene, Chinnaiyan and colleagues now have launched a new investigation into what happens post-fusion.

By using high-tech genetic mapping techniques, the research team found that once fusion takes place, androgen receptors get blocked, in turn cutting off normal prostate cell growth while permitting cancer to spread.

"Our study shows the underlying problem in prostate cancer is the presence of a gene fusion, not the androgen receptor," Chinnaiyan said in the news release. "In many contexts, androgen signaling is actually a good thing, but the presence of the gene fusion blocks androgen receptor signaling, which alters normal prostate cell development. While current treatments for advanced prostate cancer are focused on hormone deprivation and are quite effective, at least initially, future therapies need to be developed that target the prostate cancer gene fusion."

More information

For more on prostate cancer, visit the U.S. National Cancer Institute.



-- Alan Mozes



SOURCE: Cancer Cell, news release, May 19, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Scientists discover the molecular heart of collective behavior
2. Scientists Map Genetic Codes of Human Microbes
3. Scientists find protein spurs spread of prostate cancer
4. What to Read on World Ocean Day: Scientists and Non Profits Herald New Eco-Thriller Eye of the Whale
5. Clue to switch of bladder cancer from locally contained to invasive found by Jefferson scientists
6. Wistar scientists explain the persistence of melanoma through dynamic stemness
7. Mass. Eye and Ear receives NEI grant renewal for growing clinical/scientists
8. Scientists Map Neanderthal Genome
9. Genome breakthrough allows scientists to identify and profile tumor cells from very small samples
10. Scientists Unravel Secret of HIV Resistance
11. A century-old puzzle comes together: Scientists ID potential protein trigger in lung disease sarcoidosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... in many scientific laboratories. The assembly protocols involve many repetitive steps and often ... for automation, which enables the high-throughput needed, and results in a lower error ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... Hills of Pittsburgh now have easier access to the robotic-assisted total-hip and ... Health Network (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson Hospital recently ...
(Date:3/29/2017)... ... March 29, 2017 , ... AvePoint , the ... American office location in Richmond, Virginia, located at the Riverfront Plaza, 901 East Byrd ... Lieutenant Governor of Virginia Ralph S. Northam and Mayor of Richmond Levar M. Stoney. ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... Tuesday, ... asking the American public to take the Diabetes Risk Test to find out if ... the Los Angeles World Airports will light up the evening sky by programming the ...
(Date:3/28/2017)... CARTERSVILLE, Georgia (PRWEB) , ... March 28, 2017 ... ... analyst to its award-winning team. Ruel Williamson brings his extensive knowledge of appraisals, ... been a leader in the real estate valuation industry for more than 40 ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017 Varian Medical Systems (NYSE: VAR ... second quarter of fiscal year 2017 following the close of ... will be followed by a teleconference available to all interested ... link to the conference call webcast will be available on ... teleconference call and replay: ...
(Date:3/29/2017)... , March 29, 2017   Royal Philips ... in health technology, and PathAI, a company that ... with the aim to develop solutions that improve ... cancer and other diseases. The partnership aims to ... this form of artificial intelligence to be applied ...
(Date:3/29/2017)... , March 29, 2017 Neurim Pharmaceuticals ... Exeltis will obtain exclusive marketing rights for Neurim,s new Rx PedPRM ... ... targeted to treat sleep disorders in children with Autism Spectrum Disorders ... sleep medication approved for children. The collaboration with Exeltis ...
Breaking Medicine Technology: